American Oriental Bioengineering, Inc. (AOBI)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2012 | 118.72 Million USD | -35.41% |
| 2011 | 183.81 Million USD | 1.76% |
| 2010 | 180.64 Million USD | -0.43% |
| 2009 | 181.42 Million USD | 1.81% |
| 2008 | 178.19 Million USD | 338.56% |
| 2007 | 40.63 Million USD | 39.64% |
| 2006 | 29.09 Million USD | 229.98% |
| 2005 | 8.81 Million USD | -9.06% |
| 2004 | 9.69 Million USD | 206.63% |
| 2003 | 3.16 Million USD | 31.03% |
| 2002 | 2.41 Million USD | 301555.5% |
| 2001 | 800.00 USD | -99.86% |
| 2000 | 577.84 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2013 Q1 | 116.01 Million USD | -2.28% |
| 2013 Q3 | 143.94 Million USD | 22.58% |
| 2013 Q2 | 117.43 Million USD | 1.23% |
| 2012 Q1 | 183.84 Million USD | 0.01% |
| 2012 FY | 118.72 Million USD | -35.41% |
| 2012 Q4 | 118.72 Million USD | -14.99% |
| 2012 Q3 | 139.65 Million USD | -25.76% |
| 2012 Q2 | 188.1 Million USD | 2.32% |
| 2011 FY | 183.81 Million USD | 1.76% |
| 2011 Q4 | 183.81 Million USD | 1.48% |
| 2011 Q3 | 181.13 Million USD | -1.12% |
| 2011 Q2 | 183.18 Million USD | 2.44% |
| 2011 Q1 | 178.83 Million USD | -1.0% |
| 2010 Q2 | 179.39 Million USD | 0.91% |
| 2010 Q1 | 177.77 Million USD | -2.01% |
| 2010 Q3 | 183.16 Million USD | 2.1% |
| 2010 FY | 180.64 Million USD | -0.43% |
| 2010 Q4 | 180.64 Million USD | -1.38% |
| 2009 FY | 181.42 Million USD | 1.81% |
| 2009 Q1 | 170.34 Million USD | -4.41% |
| 2009 Q2 | 172.58 Million USD | 1.32% |
| 2009 Q3 | 180.22 Million USD | 4.42% |
| 2009 Q4 | 181.42 Million USD | 0.67% |
| 2008 Q1 | 40.84 Million USD | 0.53% |
| 2008 FY | 178.19 Million USD | 338.56% |
| 2008 Q4 | 178.19 Million USD | 6.65% |
| 2008 Q3 | 167.07 Million USD | 253.37% |
| 2008 Q2 | 47.28 Million USD | 15.76% |
| 2007 Q1 | 25.87 Million USD | -11.06% |
| 2007 Q2 | 28.37 Million USD | 9.63% |
| 2007 Q3 | 47.24 Million USD | 66.51% |
| 2007 Q4 | 40.63 Million USD | -13.99% |
| 2007 FY | 40.63 Million USD | 39.64% |
| 2006 Q3 | 25.99 Million USD | -11.69% |
| 2006 FY | 29.09 Million USD | 229.98% |
| 2006 Q1 | 9.73 Million USD | 10.46% |
| 2006 Q2 | 29.43 Million USD | 202.27% |
| 2006 Q4 | 29.09 Million USD | 11.91% |
| 2005 Q4 | 8.81 Million USD | -20.64% |
| 2005 Q3 | 11.11 Million USD | -6.0% |
| 2005 Q2 | 11.81 Million USD | 15.02% |
| 2005 Q1 | 10.27 Million USD | 5.98% |
| 2005 FY | 8.81 Million USD | -9.06% |
| 2004 Q3 | 3.74 Million USD | 4.69% |
| 2004 Q4 | 9.69 Million USD | 159.2% |
| 2004 FY | 9.69 Million USD | 206.63% |
| 2004 Q1 | 4.97 Million USD | 57.25% |
| 2004 Q2 | 3.57 Million USD | -28.14% |
| 2003 Q2 | 3.48 Million USD | 8.52% |
| 2003 Q1 | 3.21 Million USD | 33.07% |
| 2003 FY | 3.16 Million USD | 31.03% |
| 2003 Q4 | 3.16 Million USD | -34.52% |
| 2003 Q3 | 4.82 Million USD | 38.57% |
| 2002 Q4 | 2.41 Million USD | -8.67% |
| 2002 Q1 | 800.00 USD | 0.0% |
| 2002 Q2 | 3 Million USD | 375564.88% |
| 2002 Q3 | 2.64 Million USD | -12.08% |
| 2002 FY | 2.41 Million USD | 301555.5% |
| 2001 Q2 | 323.89 Thousand USD | -51.78% |
| 2001 Q3 | 405.62 Thousand USD | 25.24% |
| 2001 Q4 | 800.00 USD | -99.8% |
| 2001 FY | 800.00 USD | -99.86% |
| 2001 Q1 | 671.73 Thousand USD | 16.25% |
| 2000 Q2 | 762.64 Thousand USD | 24.02% |
| 2000 Q1 | 614.93 Thousand USD | 0.0% |
| 2000 Q4 | 577.84 Thousand USD | 13.97% |
| 2000 FY | 577.84 Thousand USD | 0.0% |
| 2000 Q3 | 507.01 Thousand USD | -33.52% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -432671.545% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -1154.207% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -63.82% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -14578.919% |
| Rebus Holdings, Inc. | 5.24 Million USD | -2164.827% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -101.176% |
| Qrons Inc. | 1.48 Million USD | -7874.822% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -9582.022% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -58.465% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -265521.572% |
| Skye Bioscience, Inc. | 14.07 Million USD | -743.663% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -122.722% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -1139.01% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -28062.056% |
| SQZ Biotechnologies Company | 50.03 Million USD | -137.259% |
| Intellipharmaceutics International Inc. | 12 Million USD | -888.63% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -2982.554% |
| Mesoblast Limited | 188.44 Million USD | 36.999% |
| Marizyme, Inc. | 26.67 Million USD | -345.057% |
| Genus plc | 485 Million USD | 75.521% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -1932.003% |
| Pharming Group N.V. | 244.07 Million USD | 51.358% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -5806.196% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -4618.074% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -3024.269% |
| ContraFect Corporation | 32.53 Million USD | -264.951% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -5892.113% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -3001.702% |
| IMV Inc. | 37.93 Million USD | -212.98% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -907.983% |
| MultiCell Technologies, Inc. | 1617.67 USD | -7338987.577% |
| ONE Bio Corp. | 27.49 Million USD | -331.783% |
| Accustem Sciences Inc. | 1.07 Million USD | -10900.549% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -53.354% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -5513.161% |
| Q BioMed Inc. | 8.13 Million USD | -1359.77% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -43.151% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -2207.062% |
| Biomind Labs Inc. | 1.49 Million USD | -7822.145% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -1212.98% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -545.11% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -8179.897% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -83451.299% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -58931.712% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -1966.236% |
| GB Sciences, Inc. | 5.41 Million USD | -2091.435% |
| Alpha Cognition Inc. | 7.16 Million USD | -1557.027% |
| HST Global, Inc. | 593.59 Thousand USD | -19900.61% |
| CSL Limited | 18.62 Billion USD | 99.362% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -9328.437% |
| Halberd Corporation | 728.71 Thousand USD | -16191.906% |
| Enzolytics Inc. | 365.26 Million USD | 67.497% |
| Agentix Corp. | 2.51 Million USD | -4628.923% |
| Resverlogix Corp. | 67.39 Million USD | -76.156% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -14054.965% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 73.318% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -6826.617% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -379.763% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -897.406% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -3139.206% |
| AVAX Technologies, Inc. | 3.99 Million USD | -2872.704% |
| Zenith Capital Corp. | 27.56 Thousand USD | -430536.65% |
| Genscript Biotech Corporation | 1.32 Billion USD | 91.046% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -49646.586% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -3079.231% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -17337.763% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -4278.242% |
| Kadimastem Ltd | 3.5 Million USD | -3287.353% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -177285.316% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -136.197% |
| BioStem Technologies, Inc. | 15.9 Million USD | -646.462% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -25448.197% |
| LadRx Corporation | 2.2 Million USD | -5295.17% |
| Cell Source, Inc. | 15.8 Million USD | -651.087% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2075.349% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2075.349% |
| NovAccess Global Inc. | 7.86 Million USD | -1410.32% |
| Affymax, Inc. | 8.87 Million USD | -1238.318% |
| Itoco Inc. | 1.65 Million USD | -7081.571% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -5686.91% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -1862.675% |
| Mobile Lads Corp. | 1.31 Million USD | -8938.636% |
| CytoDyn Inc. | 127.89 Million USD | 7.171% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -283931.24% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -7479.415% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -974.867% |
| SYBLEU INC | 681.41 Thousand USD | -17322.946% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -1845.658% |
| International Stem Cell Corporation | 5.27 Million USD | -2149.805% |
| Bioxytran, Inc. | 3.24 Million USD | -3553.553% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -18870.999% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -2471.345% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -189.595% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -433.224% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -5761.705% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -2067.255% |
| Neutra Corp. | 973.52 Thousand USD | -12095.037% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -309.175% |
| PureTech Health plc | 125.58 Million USD | 5.463% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -3059.922% |
| IXICO plc | 1.9 Million USD | -6147.578% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -478.315% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -14.903% |
| CSL Limited | 18.62 Billion USD | 99.362% |
| Cellectis S.A. | 249.36 Million USD | 52.391% |